Empagliflozin improves insulin sensitivity in patients with recent acute coronary syndrome and newly detected dysglycaemia

Empagliflozin reduces the risk of cardiovascular disease (CVD) in patients with type 2 diabetes (T2DM) and high cardiovascular risk via mechanisms which have not been fully explained. The mechanisms of such be...

Source: Cardiovascular Diabetology - August 11, 2023 Category: Cardiology Authors: Elena Fortin, Magnus Lundin, Linda Mellbin, Anna Norhammar, Per N äsman, Stina Smetana, Peder Sörensson, Ele Ferrannini, Lars Rydén and Giulia Ferrannini Tags: Research Source Type: research